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1. Introduction 
Crystal engineering and co-crystallization have evolved in recent years and gained a special 
interest not only in academia but also in the pharmaceutical field as it has been shown that 
the physical and pharmacokinetic properties of new crystal forms (solvates, salts, molecular 
salts, co-crystals, polymorphs) are different when compared to pure APIs1-16. Actually, 
producing co-crystals of pharmaceuticals has been reported to change their melting points3, 
solubility and dissolution rates2, 4, moisture uptake17, physical and chemical stability18 and in 
vivo exposure9, 19-21. The leading idea is that the potentiality of new different forms may open 
to innovation and new drug discoveries as well as to intellectual property protection via 
patenting of new forms of “old drugs”5, 7, 22. The diversity of forms that crystalline solids 
may attain is mainly due to non-covalent interactions resulting in different molecular 
assemblies that imply an energetic interplay between enthalpy and entropy. 
Although organic salts are traditionally the preferred crystal form of APIs because of their 
higher solubility and/or increased degree of crystallinity, the potential number of suitable 
organic salts is limited to the counterions specified by the Food and Drug Administration 
(FDA) as generally regarded as safe (GRAS). This limitation stimulates the development of 
other suitable forms and recently co-crystals have been gaining relevance in studies and 
some of them have already shown to improve therapeutic utility as well as reducing the side 
effects even when compared with marketed drugs. Consequently, APIs represent a 
particular great challenge to crystal engineers, because they are inherently predisposed for 
self-assembly since their utility is usually the result of the presence of one or more 
exofunctional supramolecular moieties. However, the crystal packing of APIs is even less 
predictable than that of other organics due to their multiple avenues for self-assembly. 
Additionally, APIs are commonly valuable chemical entities and therefore the diversity of 
the crystal forms of those molecules is of great importance for the variability of properties 
and potential intellectual property. 
Co-crystals are most commonly thought of as structural homogeneous crystalline materials 
that contain two or more neutral building blocks that are present in definite stoichiometric 
amounts and are obtained through the establishment of strong hydrogen bonds and other 
non-covalent interactions such as halogen bonds, π-π and coulombic interactions. However, 
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if the groups involved in these bonds have the tendency to transfer protons between acids 
and bases, then the result may be a molecular salt instead of a co-crystal. In principle, this 
event replaces the X-H···Y interaction by a charge assisted X-···H-Y+ hydrogen bond22.  
The formation of multicomponent crystal forms relies mainly on the hydrogen-bond 
synthons that are possible to form and their relative robustness. Hence a thorough 
datamining based on the Cambridge Structural Database (CSD)23, is required for a 
successful design of the new crystallines. One notable obstacle in the path of rational co-
crystal design is the phenomenon of polymorphism, to which organic molecules are 
predisposed. Polymorphic co-crystals are also not uncommon and a few systems have 
already been reported to date24. 
Even though co-crystals are traditionally obtained by solution techniques, often limited by 
differences in solubility of co-crystal components and/or solvent/solute interactions25, the 
best strategies to attain the desired forms consist on a judicious choice of synthetic and 
crystallization conditions, which also contemplate the environment-friendly techniques of 
mechanochemistry (neat (NG), liquid-assisted (LAG) and ion- and liquid-assisted grinding 
(ILAG)) that  have demonstrated to be an efficient method in co-crystallization screening 
and synthesis: solid-state grinding allows the formation of multicomponent forms even with 
low-solubility components that would be difficult to use with the traditional solution 
techniques; the addition of catalytic amounts of a liquid to the grinding mixture further 
improves the efficiency of grinding co-crystallization, as already proven26-30.  
Novel crystallines are usually fully characterized using powder (XRPD) and single crystal 
(SCXRD) X-ray diffraction techniques, differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA), hot-stage microscopy (HSM) and spectroscopic methods, 
such as Fourier transform infrared (FTIR) and Raman.   
A wide range of studies have been performed in the last few years, here we will focus on 
some of those we have been recently engaged. Several studies with gabapentin, a 
neuroleptic drug, have been reported31-34 and a few multicomponent crystal forms with 
carboxylic acids have been exploited and will be deeply discussed in this chapter. With the 
antibiotic 4-aminosalicylic acid (4ASA) some new crystal forms were disclosed, solvates, 
and molecular salt35, showing a clear tendency of this API to form multicomponent 
crystallines with lone-pair containing heterocycles, such as dioxane, morpholine and 
piperazine, disrupting the typical Rଶଶሺ8ሻ homosynthon in 4ASA (Figure 1).  
 
a b 
Fig. 1. (a) Rଶଶሺ8ሻ synthon in the 4ASA crystal packing; (b) disrupted ܀૛૛ሺૡሻ synthon in the 
4ASA:morpholine molecular salt.36 
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Another example is the widely used paracetamol, which also presents multicomponent 
crystal forms that were identified and characterized37-39. Perindopril erbumine is an 
antihypertensive drug existent in quite a few polymorphic forms and several hydrates were 
also disclosed40-48. A detailed discussion of some of these compounds will be addressed in 
this chapter. 
But as important as the synthesis of these new compounds is the injunction of their 
structure-properties relationships. Solubility is a major factor that is known to strongly affect 
API’s performance and therefore its correlation with structural and thermal data is of 
upmost importance.  
API coordination complexes are another related topic that has recently been disclosed as a 
new pathway for the development of improved crystal forms. In this area, as example, two 
complexes of 4ASA with silver and one complex coordinating piracetam, a nootropic API, to 
nickel were prepared and characterized49.  
2. Gabapentin: Polymorphs and multicomponent crystal forms1,2 
Gabapentin (1-(aminomethyl)cyclohexane acetic acid, GBP) is an analogue of gamma-
aminobutyric acid (GABA) and exhibits anticonvulsant properties. It is a neuroleptic drug 
prescribed for the prevention of seizure, for the treatment of mood disorders, anxiety and 
tardive diskinesia50-57, as well as for the treatment of neuropathic pain58. More recently, GBP 
has also been applied in the treatment of limb tremor59, 60. This API is highly soluble but has 
limited and variable bioavailability, probably due to its dependence on a low-capacity 
aminoacid transporter expressed in a limited region of the upper small intestine. Changes in 
solid state structure can have marked influence on the physiological absorption 
characteristics supporting the search for multicomponents crystal forms as means of 
improving the limited bioavailability of the drug7, 33, 61, 62.  
Gabapentin is known to exist in three anhydrous polymorphic forms32, 63, 64, which have 
been the object of many patent applications and issued patents. The nomenclature is not 
uniform and different publications refer to different forms making use of the same name. 
One hydrate form, labelled form I, is known65, while form II is the anhydrous commercial 
form66. The crystal structures of these forms are present in the Cambridge Structural 
Database (CSD) with the refcodes QIMKOM  for form I67 at -120°C and QIMKIG and 
QIMKIG01 for form II at -120°C67 and at RT58, respectively. Form III as labelled by Braga and 
co-workers68, has been described by Pesachovich et al 69, and its crystal structure has been 
reported by Reece and Levendis as form α70. A patent by Chen et al71. describes a new form 
of gabapentin, dehydrated A, which is consistent with form ǃ reported by Reece and 
Levendis70, labelled form IV by Braga and co-workers68. Another crystalline form of 
gabapentin was described by Lladò et al72, but its powder pattern is very similar to that of 
                                                                 
1 Adapted with permission from On the Track of New Multicomponent Gabapentin Crystal Forms: 
Synthon Competition and pH Stability,Vânia André, Auguste Fernandes, Pedro Paulo Santos, and M. 
Teresa Duarte, Crystal Growth & Design, 2011, 11 (6), pp 2325–2334,DOI: 10.1021/cg200008z. Copyright 
(2011) American Chemical Society. 
2 Adapted with permission of the Royal Society of Chemistry (RSC) from Polymorphic gabapentin: 
thermal behaviour, reactivity and interconversion of forms in solution and solid-state Dario Braga, 
Fabrizia Grepioni, Lucia Maini, Katia Rubini, Marco Polito, Roberto Brescello, Livius Cotarca, M. Teresa 
Duarte, Vânia André and M. Fátima M. Piedade New J. Chem., 2008, 32, 1788-1795, DOI: 
10.1039/B809662G. 
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form IV. Kumar et al73 reported a form of gabapentin in an international patent application 
that is most likely a mixture of forms III and IV (Figure 2). 
 
a b c 
Fig. 2. Crystals’ morphology of gabapentin polymorphs (a) II, (b) III and (c) IV. 
In all characterized forms of gabapentin the molecule crystallizes in its zwitterionic form 
and hydrogen-bonds consist of charge-assisted N+-HO- interactions all the 
supramolecular arrangements relying on chain motifs. 
Polymorph II forms double chains that can be seen along b, in which the molecules are 
oriented so that the substituent groups of the cyclohexane are turned to each other. This 
orientation of the NH3+ and COO- results in no interactions with neighboring chains along b 
and only one hydrogen bond is used to connect this chain to the parallel chain formed 
exactly in the same orientation (Figure 3). 
In the crystal structure of polymorph III molecules form a 2D sheet along b, in which the 
gabapentin molecules are organized in chains. In the same chain, molecules orient the 
substituent groups of the cyclohexane ring in the same direction, although the cyclohexane 
ring is 70.52º alternately rotated. In consecutive chains, the substituent groups are anti-
parallel oriented and there are interactions between these two chains (Figure 3).  
Several similarities between packing of both forms III and IV of gabapentin can be detected 
and, indeed, the main difference is that in the latter an intramolecular interaction is 
established. Form IV also forms chains of gabapentin molecules, in which the cyclohexane 
structures are rotated alternately rotated by 65.83º. Just as in form III, in each chain the 
substituent groups are oriented in the same direction and in the chain below have an anti-
parallel orientation. The chains are connected in pairs because of the anti-parallel orientation 
of the substituent groups, which leaves no opportunity to establish hydrogen-bonds with a 
third chain. However in this form no direct interactions between molecules in the same 
chain are observed: all of them connect with molecules in the chain above/below and that 
same molecule that interacts with “initial” molecule will also be connected to the molecule 
just besides the first one in the other chain. Consecutive parallel chains are formed just ones 
behind the others, exactly with the same orientation (Figure 3). 
Overlapping the structures of the three gabapentin’s forms (II, III and IV) it is possible to see 
that these are conformational polymorphs (Figure 4).  
In the three known polymorphs of gabapentin, the carboxylate C-O bond lengths differ by 
0.020 Å, 0.017 Å and 0.016 Å in forms II, III and V, respectively. For all these polymorphs, 
the longer bond involves the O atom that forms two NH···O contacts and the shorter bond 
is involved only in one NH···O interaction. In all the three structures, the cyclohexane ring 
adopts an almost perfect chair conformation. 
Thermal characterization of the three polymorphs is also reported68. In the first DSC heating 
cycle form II shows an endothermic peak at 158°C (Figure 5) while in the second heating 
cycle the endothermic peak is at 87°C, thus representing the melting point of gabapentin-
lactam74, confirmed by recrystallization and second heating cycle from the melt on HSM  
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a b 
c 
Fig. 3. Supramolecular arrangements of gabapentin forms (a) II, showing the double chains 
along b, with the substituent groups aligned, (b) III, showing the double chains along b, 
with the substituent groups rotated and (c) IV showing the double chains assisted by the 
intramolecular hydrogen bond. 
 
Fig. 4. Gabapentin forms II, III and IV structures overlapped. Hydrogen atoms were omitted 
for a better visualization. 
(Figure 6). The formation of gabapentin-lactam is not surprising, and it is known that 
gabapentin is unstable in aqueous solutions and undergoes an intramolecular dehydration 
reaction yielding the lactam75; the formation of gabapentin-lactam has also been observed in 
the solid state74. Therefore the endothermic peak observed in the first heating cycle does not 
correspond to the melting of gabapentin, but covers several events: the cyclization, the 
release of water and the melting of gabapentin-lactam; these events could not be separated 
even with a slow scanning rate. Form III shows a similar thermal behaviour, with a broad 
endothermic peak at 165°C, which is again due to the cyclization process with formation of 
gabapentin-lactam, water release and melting of gabapentin-lactam68. 
As noted above, the thermodynamic form II undergoes the reaction at a slightly lower 
temperature than the metastable form III. The different behaviour might be explained by the 
slightly different pattern of hydrogen bonds in their crystal structures70.  
Form II 
Form III 
Form V
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Fig. 5. DSC traces (open pan) of gabapentin Form II (a), with onset temperature = 158.0°C 
and peak temperature = 161.1°C, and of gabapentin Form III (b), with onset temperature = 
165.0°C and peak temperature = 166.6°C68. 
 
a b 
Fig. 6. Hot-stage microscopy of crystalline gabapentin-lactam (a) as obtained in the first DSC 
heating cycle of gabapentin, showing melting at 89°C (b)68. 
Several attempts to produce pure form IV in reasonable quantity to be used in DSC 
measurements were not successful; still a HSM experiment on single crystals of form IV 
isolated within an oil drop was possible. Figure 7 clearly shows the release of water as gas 
bubbles in the temperature range 152-155°C, immediately followed by melting of the 
gabapentin-lactam thus formed68. 
 
 
a b c 
Fig. 7. Hot-stage microscopy on gabapentin form IV crystals (preserved in Fomblin oil): (a) 
single crystal at 32ºC, (b) evolution of water bubbles at 153ºC  and (c) complete melting of 
gabapentin-lactam at 157ºC (amplification 100x)68.  
The unique presence in crystals of form IV of an intramolecular N-H···O hydrogen-bond, 
associated with a smaller number of intermolecular hydrogen bonds with respect to the 
other two forms, must be responsible for the lower reaction temperature observed70.  
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Furthermore, a monohydrate76-78, two polymorphic chloride hemihydrates58, 63, 79, 80 an 
hemisulfate hemihydrate79, 80 and an heptahydrate under high pressure81 forms are also 
known. Coordination complexes of this API with Cu and Zn were isolated and 
characterized82. An extensive pH stability of gabapentin has been disclosed where an ester 
derivative obtained at low pH was reported83. 
Multicomponent crystal forms (co-crystals and molecular salts) involving GBP with 
different carboxylic acids were also recently disclosed1, 32-34. 
A search in the Cambridge Structural Database (CSD)23 (July 2011) has shown that the ܴସଶሺ8ሻ 
synthon is the most common between cationic amine and carboxylate moieties. The 
expected synthons to be formed between the API and the coformers should be based on 
carboxyl···carboxylate and amine···carboxylate interactions. Accordingly to a CSD23 survey 
(July 2011), the preferred interactions should be amine···carboxylate  followed by the 
carboxyl···carboxylate.  
Therefore, carboxylic acids were chosen as potential coformers of multicomponent crystal 
forms of gabapentin. Mono and di-carboxylic acids bearing one or more hydroxyl moieties 
have previously been exploited by Reddy et al33 revealing an important role of the OH 
group in the supramolecular arrangements of the new forms. A series of mono-, di- and 
tricarboxylic acids, without further hydroxyl moieties, were considered by André et al84 to 
exploit the use of one or more equivalents of carboxylic moieties avoiding the hydroxyl 
competition.  
Five new multicomponent crystal forms of the neuroleptic drug gabapentin with isophthalic 
acid (pKa1=3.5; pKa2=4.585), phthalic acid (pKa1=3.0; pKa2=5.385), L-glutamine (pKa1=2.1; 
pKa2=4.385), terephthalic (pKa1=3.5; pKa2=4.585) and trimesic (pKa1=3.1; pKa2=3.9; 
pKa3=4.785) acids have been reported and are characterized by XRPD. Despite all the 
crystallization attempts, single crystals suitable for SCXRD were only grown for the 
compounds with terephthalic (4) and trimesic (5) acids, which are further characterized by 
SCXRD, DSC, TGA, HSM and IR. The strong homomeric ܴଶଶሺ8ሻ and heteromeric ܴସଶሺ8ሻ 
synthons observed in the carboxylic acids and gabapentin, respectively, were disrupted and 
competing synthons based on carboxyl···carboxylate and amine···carboxylate interactions 
were formed in the new crystallines with trimesic and terephthalic acids84.  
With L-glutamine, a new crystal form 1 characterized by XRPD is obtained by solution 
techniques. Both solution and LAG experiments with phthalic acid resulted in a mixture of 
the coformer and a new crystalline 2. With isophthalic acid, a mixture of a new crystal form 
3, isophthalic acid and gabapentin polymorph III was identified. In this case, the yield of the 
supramolecular reaction is low and both reagents are also detected, though gabapentin is 
detected in a different polymorphic form from the starting material. The full conversion into 
the new form with terephthalic acid, 4, was only attained by LAG, as terephthalic acid 
displays solubility problems and showing not only that the formation of this salt is 
independent of reactional pH but also the advantage of this method when using highly 
insoluble compounds. The multicomponent crystal form comprising gabapentin and 
trimesic acid, 5, was obtained as a single phase both by solution and LAG techniques 
(Figure 8). 
The asymmetric unit of 4 consists on one gabapentin cation and half a terephthalic acid 
anion residing on an inversion centre. In this structure there is clear evidence of proton 
transfer between both compounds within the structure and thus this form a molecular salt.  
Gabapentin cations are connected to terephthalic anions through three different charge-
assisted interactions (Scheme I.a), two of which involve the protonated amine moiety of the  
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a b 
Fig. 8. (a) Experimental XRPD patterns obtained from mechanochemistry (blue); a mixture 
of gabapentin polymorph III and 4 obtained by solution techniques (black); and gabapentin 
polymorph III (green); theoretical XRPD patterns obtained from SCXRD data of 4, at 150K 
(pink); (b) Experimental XRPD pattern obtained from 5 obtained by LAG (blue) and solution 
(black) techniques; theoretical powder diffraction pattern obtained from single-crystal data, 
at 150K (pink). 
 
Scheme I. Main hydrogen bond interactions present in molecular salt 4 
API and the carboxylate of the anion, N+HGBP···O-TA, and a third one concerning the 
carboxylic group of GBP and again the carboxylate of terephthalic acid, OHGBP···O-TA 
(Figure 9.a). The donor group – either the amine and/or the carboxylic moiety – belong to 
GBP, while the carboxylate groups of terephthalic acid always act as acceptors, with O3 
behaving as a bifurcated acceptor.  
Gabapentin cations interact among them by the N+HGBP···OGBP interactions (Scheme I.b), one 
of them being slightly longer. It is possible to see that these interactions among four 
gabapentin cations form a tape supported by ܴସସሺͳʹሻ synthons growing along c (Figure 9.b).  
The interplay of these hydrogen bonds gives rise to terephthalic acid anions acting as 
spacers between GBP cationic tapes, very clear in a view along the b axis (Figure 9.c). Within 
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the terephthalic acid row, the anionic spacers alternate with a rotation of 27°; it can also be 
seen that in the gabapentin tape cations are rotated by 39°. 
The formation of GBP tapes is a common pattern both in the structure of the three 
polymorphs of gabapentin and in 4, in the latter the coformer links consecutive tapes. The 
formation of 4 disrupts the ܴଶଶሺ8ሻ synthons typical of the terephthalic acid while increasing 
the number of hydrogen-bond interactions in which gabapentin is involved when compared 
with any of the three known polymorphic forms. 
 
 
Fig. 9. Packing diagrams obtained from 4; (a) detailed hydrogen-bonding system in 4, (b) 
view showing the cationic GBP tape and depicting ܴସସሺͳʹሻ synthons represented in blue, (c) 
view along b of the supramolecular packing where the spacer function of the coformer is 
clear. Color code: green – GBP; blue – coformer. 
Asymmetric unit of crystalline 5 consists of one gabapentin zwitterion, one trimesic acid 
molecule and one water molecule. In this structure there is clear evidence that the proton 
transfer occurs within gabapentin, resulting in its zwitterionic form; therefore all the molecules 
involved in this structure are globally neutral and thus we have a hydrated co-crystal. 
An intramolecular hydrogen bond is established in each gabapentin molecule [N+HGBP···O-
GBP] and gabapentin zwitterions interact among them using the amine and the carboxylate 
moieties, N+HGBP···O-GBP. Both interactions are responsible for the formation of dimers 
based on ܴସଶሺ8ሻ synthons (Scheme II.a). 
Two of the carboxylic acid groups of trimesic acid are used to form the usual ܴଶଶሺ8ሻ synthon 
through OHTA···OTA. The third COOH no longer maintains this typical pattern but interacts 
with three independent gabapentin zwitterions (Scheme II.b), two of which are involved in 
the previously mentioned GBP ܴସଶሺ8ሻ dimer. In these GBP···TA interactions, C=O acts as an 
acceptor for one NH of gabapentin [N+HGBP···OTA]; OH works both as acceptor, from 
another gabapentin’s amine moiety [N+HGBP···OTA], and as donor to a CO of a third 
gabapentin molecule [OHTA···O-GBP] (Figure 10.a). A tape of GBP zwitterionic dimers 
assisted by trimesic acid moieties is formed (Figure 10.b). Actually these tapes are further 
reinforced by water molecules as each gabapentin zwitterion interacts with three water 
molecules via N+HGBP ···OW and two OHW···O-GBP (Scheme II.a).  
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The supramolecular arrangement of 5 can be described as alternated gabapentin 
zwitterionic ondulated chains and trimesic acid zigzag chains, with water molecules lying in 
the space between them (Figure 10.c). Trimesic acid besides supporting the gabapentin tapes 
also acts as spacer between them, similarly to compound 4. 
Comparing this structure with the three known GBP polymorphs, the intramolecular bond 
is similar to the one formed in polymorph IV and the Rସଶሺ8ሻ  synthons are observed also in 
polymorph III. The typical Rଶଶሺ8ሻ synthon between trimesic acid molecules is maintained in 
2/3 of its interactions and it is only disrupted to establish connections with GBP zwitterions, 
increasing the number of hydrogen-bonds in which they both are involved. 
The presence of the intramolecular bond in gabapentin zwitterions could suggest an 
analogue conformation of GBP molecules in this co-crystal and in polymorph IV, but this is 
not observed and, in fact GBP adopts different conformations.  
 
 
Scheme II. Main hydrogen bond interactions present in 5. 
 
 
Fig. 10. Packing diagrams for co-crystal 5 (a) detailed hydrogen-bonding system in 
GBP:trimesic acid hydrate; (b) view along b showing both the tape made of GBP dimers 
assisted by water and trimesic acid spacers; (c) space filling diagram viewed along the c-
axis. Color code: green – GBP; blue – coformer; red- water. 
a b
_
_
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In both gabapentin multicomponent crystals’ structures 4 and 5, gabapentin’s cyclohexane 
ring adopts a chair conformation in which the aminomethyl group is in an equatorial 
position, with the carboxymethyl group in the axial position. The relative positioning of the 
substituent groups is similar to the one observed in gabapentin polymorph IV; in the other 
two polymorphic forms of gabapentin the aminomethyl and carboxymethyl groups occupy 
the inverted positions (Figure 11).  
 
 
Fig. 11. A comparison of the GBP conformation in: (a) GBP:terephthalic acid molecular salt; 
(b) GBP:trimesic acid co-crystal; (c) GBP polymorph II; (d) GBP polymorph III; (e) GBP 
polymorph IV. C-C-N bond angles are given in blue and both C-C-C-O dihedral angles in 
black84.  
Analyzing all the unveiled multicomponent forms of gabapentin32-34, 58, 63, 76, 79, there was no 
systematic behavior concerning the relative positioning of the aminomethyl and 
carboxymethyl substituent groups, what can lead us to conclude that this is governed by the 
supramolecular interactions. 
As expected the carboxylate···amine interactions in GBP and the Rଶଶሺ8ሻ in the carboxylic 
acids are partially disrupted and new hydrogen-bonding patterns were induced by the 
introduction of the coformer. Although there is proton transfer in 4 and not in 5, in both 
forms GBP interacts with the acid coformer through carboxyl···carboxylate and 
amine···carboxyl/carboxylate synthons represented in Scheme III. The interactions via 
synthons I and II are in agreement with the results previously presented by Reddy et al33 
and Kavuru et al86. 
 
 
Scheme III. Main hydrogen bonded synthons observed in 4 and 5. 
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Thermal studies were performed on the new crystal forms 4 and 5 and a combination of 
DSC, TGA and HSM data allowed some conclusions on the thermal stability of these 
compounds. The thermogram of 4 (Figure 12.a) is characterized by an endothermic peak at 
150ºC, corresponding to the melting of the compound. The melting peak is found at a lower 
temperature than any of the reported polymorphic forms of gabapentin32 and within the 
range obtained for other multicomponent forms33, 34. This peak encloses the cyclisation/ 
lactamization of gabapentin32 implying water release that is observed on HSM experiments 
(Figure 13) and detected in TGA.  
The thermogram obtained from 5 (Figure 12.b) is characterized by a wide bump between 70 
and 120°C and one broad endothermic peak at 159ºC. The first peak is due to the slow release 
of crystallization water and the second peak encloses lactamization of gabapentin and melting 
as seen in 4. Both these phenomena are supported by TGA and HSM (Figures 12 and 14).  
 
 
a b 
Fig. 12. DSC and TGA obtained for (a) molecular salt 4, and (b) co-crystal 5. 
As previously mentioned, HSM experiments with compounds 4 and 5 were also performed 
and are in agreement with what was observed in the DSC and TGA experiments and were 
used in the interpretation of these results. 
 
 
Fig. 13. HSM images for 4 at a) 25 ºC; b) 140ºC – water being released in the lactamization 
process; c) 144.5ºC – crystal appearance just before melting84. 
 
Fig. 14. HSM images for 5 at a) 25 ºC; b) 90ºC – slow release of crystallization water; c) 160ºC 
– lactamization and melting84. 
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IR spectroscopy (Figure 15) complemented the characterization of the new crystal forms 4 
and 5. In both spectra, the presence of the NH3+ group is evidenced by the peaks 
corresponding to the symmetric and antisymmetric bending frequencies (1500 and 1610 cm-
1) and by the peak corresponding to the stretching frequency (2650 cm-1). In 4, the 
carboxylate group of the acid and the carboxylic group of the API are also well 
distinguished: the carbonyl band is exhibited at frequency > 1700 cm-1 typical of a aliphatic 
carboxylic group; proton transfer between the coformer and the API is confirmed by the 
presence of coformer carboxylate bands together with the absence of the carbonyl band 
typical (1680 cm-1) of the terephthalic group. In 5, although a clear identification of the 
carboxylate of the API and the carboxylic group of the acid is not so ascertained, it is 
possible to note the absence of the carboxylic moiety of gabapentin and identify, by 
comparison with the spectra of the pure coformer, the peak of the carboxylic moieties of 
trimesic acid; therefore the existence of the carboxylate in gabapentin is inferred. 
 
 
 
a b 
Fig. 15. IR spectra for 4 (a) and 5 (b) obtained by liquid-assisted grinding84. 
The solubility of the new multicomponent forms is lower than that for gabapentin, as 
desired. As previous studies on gabapentin indicate that this API is especially dependent on 
the pH of the environment31, pH dependent stability of these two new forms was also 
studied and significant differences were found for 4 and 5, the first being stable in quite a 
narrower pH range (Figures 16 and 17).  
 
 
 
 
 
Fig. 16. pH dependent stability of 4 
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Fig. 17. pH dependent stability of 5. [Ester derivative reported in83] 
3. Perindopril: polymorphs and hydrates3 
Perindopril, 2-methylpropane-2-amine-(2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-ethoxy-carbonyl-butyl] 
amino]propanoyl]octahydro-1H-indole-2-carboxylic acid, is an antihypertensive drug that 
acts through the inhibition of angiotensin converting enzyme (ACE), a zinc metalloenzyme 
involved in the control of blood pressure. It is effective in the treatment and prevention of 
several medical conditions, such as reducing blood pressure, reversing abnormalities of 
vascular structure and function in patients with essential hypertension, congestive heart 
failure, post-myocardial infarction and diabetic nephropathy87-91. Perindopril along with 
ramipril were associated with lower mortality than most other ACE inhibitors92. Besides the 
antihypertensive properties, it also comprises vasculoprotective and antithrombotic effects, 
playing a favourable role in terms of cardiovascular morbidity93-99.   
This API is, in fact, an acid-ester prodrug that is converted into the active diacid 
perindoprilat by hydrolysis promoted by the liver esterases after administration93, 100. It is 
orally administered in the form of tablets containing its 1:1 salts with erbumine (tert-
butylamine) (Aceon®) or L-arginine (Coversyl®)43, 101. The perindopril L-arginine salt is 
equivalent to perindopril erbumine (Figure 18) but it is more stable and therefore it can be 
distributed to all the climatic zones without the need for specific packaging101.  
Over the last years, several forms of perindopril erbumine have been disclosed and several 
patents have been filed mainly based on their typical powder XRPD patterns44, 45, 102-105. 
Perindopril erbumine is known to exist in several polymorphic forms46, 48, 102, 103, 105-107, as 
well as mono-, di- and sesqui-hydrated forms, characterized by XRPD, vibrational 
spectroscopy and thermal analysis methods47, 108. Also amorphous compositions have been 
patented42 as well as a perindopril tosylate form109.  
Some of the different pharmacological and adverse effects exerted by ACE inhibitors may 
depend on the different phisicochemical (solubility, lipophilicity, acidity) and 
pharmacokinetic (absorption, protein binding, half-life and metabolic disposition) properties 
but also on their ability to penetrate and bind tissue sites110. Theoretical studies on pKa, 
lipophilicity, solubility, absorption and polar surface of ACE inhibitors, including 
perindopril, and its active metabolite, perindoprilat, have been reported111. In 2009, Remko 
presented theoretical calculations of molecular structure and stability of the arginine and 
erbumine salts of perindopril43.  
                                                                
3 Adapted with permission from First Crystal Structures of the Antihypertensive Drug Perindopril 
Erbumine: A Novel Hydrated Form and Polymorphs ǂ and ǃ, Vânia André, Luis Cunha-Silva, M. 
Teresa Duarte, and Pedro Paulo Santos, Crystal Growth & Design, 2011, 11 (9), pp 3703–3706, DOI: 
10.1021/cg200430z. Copyright (2011) American Chemical Society”. 
www.intechopen.com
Novel Challenges in Crystal Engineering: Polymorphs 
and New Crystal Forms of Active Pharmaceutical Ingredients 83 
 
Fig. 18. Chemical diagram of perindopril erbumine salt. 
Careful searches in the literature and in the Cambridge Structural Database112 revealed that, 
although this API is known since 1981, until very recently only the crystal structure of 
perindoprilat, the pharmacologically active compound, had been determined in 199193. In 
2011, Remko and co-workers41 unveiled the crystal structure of perindopril erbumine 
dehydrate.   
Also in 2011, during a polymorphic screening of perindopril erbumine, the molecular 
structures of its ǂ and ǃ polymorphs45, 113 have been determined by SCXRD as well as an 
unprecedented hydrated form of formula (C4H12N)(C19H31N2O5)·1.25H2O40, 114. Elemental 
and Karl-Fischer analyses confirmed the water contents of the three forms, that were were 
fully characterized by XRPD, vibrational spectroscopy (ATR-FT-IR and FT-Raman) and 
thermal analysis methods (TGA, DSC and HSM)40. Furthermore, stability, solubility and 
dissolution profile studies were performed. 
The crystal packing of polymorphic forms α and β show similar hydrogen bonding 
interactions involving the perindopril and the erbumine ions. Perindopril anions interact 
with erbumine cations in an extended NH···O hydrogen bonding network leading to a 
supramolecular structure with the moieties organized in a double-chain arrangement. Each 
erbumine cation connects with three perindopril anions via the amine moiety: two of them 
are in the same chain whereas the other perindopril belongs to the opposite chain where the 
positioning of the anions in their respective chains, it is possible to notice that they assume 
antiparallel orientations i.e., perindopril anions of one chain are rotated of 180º relatively to the 
anions in the adjacent chain. Consequently two related types of ܥଶଶሺ6ሻ synthons are formed in 
both chains that are connected among them by ܦଵଵሺʹሻ motifs. 
The NH···O hydrogen bond distances are within the ranges of 2.707 - 2.803 Å and 2.738 - 
2.788 Å in α and β forms, respectively. These double-chains do not establish classical 
hydrogen bonds among them neither in α nor β forms.  
The new 1:1:1.25 hydrated form crystallizes with a triclinic symmetry, in the P1 chiral space 
group. This hydrated form was obtained both by solution and by LAG, which, as previously 
said, has several advantages not only in the preparation process, where equally yield and 
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purity are obtained, but also in an environmental context115-119. Its asymmetric unit consists 
of two crystallographic independent perindopril anions, two erbumine cations and 2.5 water 
molecules. The CO distances in the carboxylate moiety and the location of the three 
hydrogen atoms in the amine moieties from the electron density map confirmed the 
presence of the salt.  
The chiral centers in both perindopril crystallographic independent anions of the hydrated 
form exhibit the (S) configuration, corresponding exactly to the same configuration of the 
starting form α as well as of form β, what is important to assure the pharmacological activity 
of the API (Figure 18). The main conformational differences between these crystallographic 
independent anions are noted in the –CH2CH2CH3 terminal groups (torsion angles of -
58.2(4)° vs 175.1(9)°). The crystal packing of this hydrated form is very similar to the one 
described for polymorphic forms α and β, involving similar hydrogen bonding interactions 
between the perindopril and the erbumine ions (Figure 19). The NH···O hydrogen bond 
distances are within the ranges of 2.75 - 2.781 Å. The main difference between this hydrate 
and the polymorphs previously described is that while the double-chains do not establish 
classical hydrogen bonds among them neither in α nor β forms, in the hydrated form water 
molecules play an important role by linking adjacent chains through interactions between two 
crystallographically independent perindopril anions via the carbonyl group of one [OW···OC=O 
distance of 2.717Å] and the amine moiety of the other [NN-H···OW distance of 2.430Å]. Water 
molecules lie in the free spaces arising from the supramolecular arrangement described 
(Figure 19) and interact through cooperative OW–H···OW hydrogen bonds forming trimeric 
water clusters [O···O distances in the cluster: 2.644, 2.687 and 2.932 Å] (Figures 19 and 20).  
Vibrational spectroscopy (FT-IR and FT-Raman) studies support the structural features 
unveiled by SCXRD data which are reflected in the spectra through a number of diagnostic  
 
 
a b 
Fig. 19. Crystal packing of the novel hydrated form of perindopril erbumine (1:1:1.25): (a) 
supramolecular arrangement with the perindopril anions and erbumine cations organized 
in double-chains; H bonds represented as blue dashed lines; water molecules were omitted 
for clarity; (b) detailed hydrogen bonding within the water cluster. Only hydrogen atoms 
involved in hydrogen bonding are shown, with exception of water molecules for which no 
hydrogen atoms are displayed40. 
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Fig. 20. Crystalline packing of the novel hydrated form of perindopril erbumine (1:1:1.25): 
Double-chain array formed by 22(6)C and 
1
1(2)D motifs is highlighted in blue40. 
 
a b 
Fig. 21. (a) DSC and (b) TGA pattern for all the forms of perindopril erbumine discussed. 
bands (Figure 21). In particular the strong bands in the range of 3200-2600 cm-1 of the FT-
Raman spectra are attributed to the υs(C–H) and υs(N–H) stretching vibrational modes 
diagnosing the presence of NH and NH3+ groups in the perindopril and erbumine cation, 
respectively. The strong bands around 1642, 1569 cm-1 and 1387 cm-1 (observed in both the 
FT-IR and FT-Raman spectra) are assigned to the υs(COO-) and υas(COO-) respectively, 
confirming the deprotonation of the carboxylic acid group. Contrasting with the FT-IR 
spectra of forms ǂ and ǃ, the spectrum of the hydrated form in the 3200-2600 cm-1 range 
reflects the presence of crystallization water molecules involved in well defined hydrogen 
bonds, by the presence of resolved peaks. 
The combination of data obtained from DSC, TGA and HSM indicates that the novel 
hydrated form is stable until approximately 80°C, temperature at which a peak is observed 
in the DSC (Figure 21.a), a smooth mass loss is detected in the TGA (Figure 21.b) and 
bubbles start to appear in the HSM. The water loss occurs from this temperature until 
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approximately 120°C. At 164ºC melting and decomposition take place. TGA for forms α and 
β reveals that there is no mass loss before 120°C, confirming the absence of water in both 
these forms. 
The new 1:1:1.25 hydrate has shown to be as stable on shelf as form α for eighteen months 
and water slurry experiments revealed that it as a thermodynamically stable form. It has 
also shown to have a similar dissolution profile (Figure 22) as the commercially available 
drug and to be slightly more soluble in water than the α form40. 
 
 
Fig. 22. Dissolution profile for the 1:1:1.25 hydrated form. 
A probable reason for this is the enhanced stability provided by the presence of the water 
molecules linking the erbumine-perindopril double chains. Analysis of crystal structure has 
again proven to be quite important for the establishment of the intermolecular interactions 
responsible for the supramolecular arrangement and thus the physicochemical properties of 
APIs.  
4. Concluding remarks 
Over the last two decades crystal engineering, a key tool for the design of new crystal forms, 
has made possible the synthesis of novel pharmaceutical materials as well as molecular level 
control of crystallization and phase transformations. Advances in crystal engineering and 
supramolecular chemistry invite us to consider new perspectives and perhaps definitions of 
the various solid-state forms that the same and/or different molecules may adopt in terms 
of molecular assemblies and architectures.  
Pharmaceutical co-crystals have proven to offer potential benefits of superior efficacy, 
solubility and stability in drug formulation. It seems reasonable to assert that co-crystal 
approaches should be considered routinely as part of a broader set of form and formulation 
explorations to achieve the best possible drug products. Although the interest in co-crystals 
and polymorphs and their utility is obvious, identifying and implementing an efficient 
discovery and control method remains a challenge. 
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